Dialysis industry news

Stories from the dialysis comunity across the globe.



Can DaVita healthCare Partners Inc. (NYSE:DVA) Surprise Analysts? - Investor Newswire PDF Print

The earnings surprise factor represents the difference between a company’s actual reported numbers and the expected consensus numbers provided by analysts on Wall Street. A large surprise factor can often result in a sharp movement in the stock price following an earnings report. Most recently DaVita healthCare Partners Inc. (NYSE:DVA) reported quarterly earnings of $0.86 for the quarter ending on 2015-03-31, yielding a surprise factor of 1.18% as the actual reported number was $0.01 away from the consensus estimates. The revenue surprise factor in per share dollar terms was $25.273 for the last quarter or 0.774%.

DaVita healthCare Partners Inc. (NYSE:DVA) is next slated to report earnings for the current quarter on 2015-07-30. Brokerages covering the stock are currently expecting the firm to earn $0.94 per share based on the 6 covering brokerages weighted into that average. Investors will be closely watching how this number fluctuates leading up to the reporting date as analysts continuously update their models.

Over the next 12-months sell-side research firms are predicting that the stock will reach targets in the range of $83-96. The average number of the range is $89 based on the 6 firms offering price targets. Placing these targets into a simplified 1-5 rating system produces a score of 1.8 for DaVita healthCare Partners Inc., where 1 represents a Strong Buy rating and 5 would indicate a Strong Sell rating. Three months ago the rating mean stood at 1.8. DaVita HealthCare Partners Inc., formerly DaVita Inc., is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). As of December 31, 2011, the Company provided dialysis and administrative services through a network of 1,809 outpatient dialysis centers located in the United States throughout 43 states and the District of Columbia, serving a total of approximately 142,000 patients. It also provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services throughout the United States. In July 2013, DaVita, a division of DaVita HealthCare Partners Inc announced the acquisition of the dialysis operations of Malaysia’s Caring Dialysis Centre Group (CDC Group) by DVA (Malaysia) Sdn Bhd.

...

 
Complications More Likely After Radiotherapy vs. Surgery for PCa - Renal and Urology News PDF Print
June 29, 2015 Complications More Likely After Radiotherapy vs. Surgery for PCa - Renal and Urology News
Radiation treatment is associated with an increased risk of requiring minimally invasive urologic procedures.

Prostate cancer (PCa) patients who undergo radiotherapy have a higher incidence of subsequent minimally invasive urologic procedures for treatment-related complications compared with those who undergo surgery, new data presented at the Canadian Urological Association annual meeting in Ottawa suggest.

Patients treated with radiation also have a higher incidence of rectal-anal procedures and hospital admissions, but they have a lower incidence of major surgical procedures compared with surgery patients, according to findings presented by investigator Christopher J. D. Wallis, MD, of the University of Toronto.

Dr. Wallis and his colleagues used the Surveillance, Epidemiology and End Results (SEER)-Medicare registry to conduct a retrospective cohort study of 60,476 men aged 65–79 years who underwent radical prostatectomy (RP) or radiotherapy (either external beam or brachytherapy) for clinically localized PCa. Of these men, 14,492 underwent primary RP and 45,984 underwent primary radiotherapy. The researchers estimated the incidence of urologic procedures and hospital admissions for complications other than erectile dysfunction or urinary incontinence.

After adjusting for age, ethnicity, marital status, comorbidities, and rural residence, radiotherapy patients had a significant 25% and 40% increased risk of requiring minimally invasive urologic procedures and rectal-anal procedures, respectively, and a significant 80% increased risk of hospital admission compared with RP patients. The radiotherapy patients had a significant 10% decreased risk of requiring major surgical procedures.

The investigators found that the rate of complications in both treatment arms peaked within 2 years of treatment but continued at a steady rate for the next 10 years.

...

 
Enzalutamide Superior to Bicalutamide for mCRPC - Renal and Urology News PDF Print
June 29, 2015 Enzalutamide Superior to Bicalutamide for mCRPC - Renal and Urology News
In a phase 2 trial, enzalutamide treatment was associated with significantly longer progression-free survival.

Enzalutamide is significantly more efficacious than bicalutamide in the treatment of metastatic castration-resistant prostate cancer (mCRPC), according to study findings presented at the Canadian Urological Association annual meeting in Ottawa.

A randomized double-blind phase 2 trial comparing the medications in 375 mCRPC patients showed that the 184 patients treated with enzalutamide had a significantly longer median progression-free survival (the primary trial endpoint) than the 191 bicalutamide recipients (15.7 vs. 5.8 months), reported investigator D. Robert Siemens, MD, of Queen's University in Kingston, Ontario. This difference translated into a 56% decreased risk of progression. In addition, the median time to PSA progression was significantly longer in the enzalutamide than bicalutamide group (19.4 vs. 5.8 months). A 50% or greater PSAresponse was achieved in 82.1% of the enzalutamide group compared with 20.9% of the bicalutamide group. The enzalutamide group had a higher rate of serious adverse events (31.1% vs. 23.3%).

In the study, the dosages of enzalutamide and bicalutamide were 160 mg per day and 50 mg per day, respectively.

...

 
Erectile Dysfunction Medications Don't Raise Melanoma Risk - Renal and Urology News PDF Print
June 29, 2015 Erectile Dysfunction Medications Don't Raise Melanoma Risk - Renal and Urology News
Men taking erectile dysfunction drugs had slightly higher odds of melanoma but lifestyle factors are the more likely culprit.

(HealthDay News) -- A new review of data involving over 20,000 men does find a slightly higher risk of melanoma in men who took erectile dysfunction (ED) medications versus those who didn't; however, the increased risk is tied to lifestyle factors rather than the medications themselves. The findings were published in the Journal of the American Medical Association.

Stacy Loeb, M.D., a urologist with NYU Langone Medical Center in New York City, and colleagues looked at federal data from Sweden on melanoma cases, and on Swedes' medication use. They specifically focused on the records of 20,325 Swedish men, most of whom were white. Between 2006 and 2012, 4,065 of the men were diagnosed with melanoma, the records showed. By cross-referencing the 2,148 men who had taken Viagra, Levitra, or Cialis with the melanoma group, the team determined that 435 men who'd been treated with ED medications also developed skin cancer.

Overall, men who took an ED drug did have a 21% higher risk for melanoma than those who did not, the researchers found; however, the study could not prove cause-and-effect. Furthermore, Loeb's team found no evidence of a dose-response relationship. The team also noted that among men taking ED drugs, the risk for basal cell carcinoma was almost exactly the same (19%) as it was for melanoma. That observation also undermined the notion that the drugs themselves contributed to the men's skin cancer risk, Loeb's team said.

"We found that the men at greatest risk for melanoma generally had higher educational backgrounds and higher incomes," Loeb told HealthDay. Factors such as those tend to translate into having more available leisure time in general -- and greater exposure to the sun. Both of those factors "were strong predictors of getting skin cancer and taking erectile dysfunction drugs," which tend to be relatively expensive medications, Loeb added.

Source

  1. Loeb, S, et al. JAMA. 2015;313(24):2449-2455; doi:10.1001/jama.2015.6604.

...

 
Falcon Physician Honored As Gold Stevie® Award Winner In 2015 American ... - MarketWatch PDF Print


                  DENVER, June 29, 2015 /PRNewswire/ -- Falcon Physician was presented with a Gold Stevie® Award in the Information Technology Department of the Year category at the 13th Annual American Business Awards in Chicago.


                  Falcon Physician was nominated for the award thanks to several major achievements in 2014. These include the release of an iPad application for dialysis rounding, improvements to the Falcon Physician Platinum electronic health record (EHR) that resulted in time-savings for users, Meaningful Use Stage 2 certification for Falcon Physician tools, and creation of a smartphone app for dialysis order review and signing as well as access to patient summaries (released in April 2015).


                  "Our development department went above and beyond the call of duty this year to provide tools that offer a better experience for nephrologists in order to improve patient care," said Derek Schoonover, Falcon Physician vice president. "We are proud of our achievements in 2014 and are honored by this recognition as we remain committed to continuous improvement in the ever-changing health care IT landscape."


                  Javier Rodriguez, CEO of DaVita Kidney Care, said "Falcon Physician is an integral part of our mission to transform healthcare. We are pleased with the recognition of Falcon's innovative work in IT, and will continue our journey of continuous improvement."


                  The American Business Awards are the nation's premier business awards program. All organizations operating in the U.S.A. are eligible to submit nominations – public and private, for-profit and non-profit, large and small. 


                  Nicknamed the Stevies for the Greek word meaning "crowned," the awards were presented to winners during a gala banquet on Monday, June 22 at the Fairmont Chicago Millennium Park Hotel.  More than 400 nominees and their guests attended.  


                  The 2015 American Business Awards will be presented at two awards events: Monday's banquet in Chicago, and at the new products awards banquet on Friday, September 11 in San Francisco.


                  More than 3,300 nominations from organizations of all sizes and in virtually every industry were submitted this year for consideration in a wide range of categories. Falcon Physician was nominated in the Information Technology Department of the Year category for organizations with 100-2,500 employees. More than 200 executives worldwide participated in the judging process to select this year's Stevie Award winners.


                  "We are extremely impressed with the quality of the entries we received this year. The competition was intense and every organization that won should be proud," said Michael Gallagher, president and founder of the Stevie Awards. "To those outstanding individuals and organizations that received Gold, Silver, and Bronze Stevie Awards, the judges and I are honored to celebrate your many accomplishments. You are setting a high standard for professionals nationwide."


                  Details about The American Business Awards and the lists of Stevie winners who were announced on June 22 are available at www.StevieAwards.com/ABA.    


                  
        About Falcon PhysicianThe Falcon Physician product suite integrates with the dialysis center and doctor's office managing kidney patients' health records from CKD through ESRD and can be accessed wherever there is internet access. Developed, tested, and endorsed by nephrologists, Falcon is supported by a dedicated team of health technology experts. For more information, email 
 This e-mail address is being protected from spambots. You need JavaScript enabled to view it
  or call (877) 99-FALCON.


                  
        About DaVita HealthCare PartnersDaVita HealthCare Partners Inc., a Fortune 500® company, is the parent company of DaVita Kidney Care and HealthCare Partners. DaVita Kidney Care is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. As of March 31, 2015, DaVita Kidney Care operated or provided administrative services at 2,197 outpatient dialysis centers located in the United States serving approximately 174,000 patients. The company also operated 93 outpatient dialysis centers located in 10 countries outside the United States. HealthCare Partners manages and operates medical groups and affiliated physician networks in Arizona, California, Nevada, New Mexico, Florida and Colorado in its pursuit to deliver excellent-quality health care in a dignified and compassionate manner. As of March 31, 2015 HealthCare Partners provided integrated care management for approximately 830,000 patients. For more information, please visit DaVitaHealthCarePartners.com.


                  
        About The Stevie Awards
          
Stevie Awards are conferred in six programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, The American Business Awards, The International Business Awards, the Stevie Awards for Women in Business, and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 10,000 entries each year from organizations in more than 60 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com. Sponsors and partners of The 2015 American Business Awards include BizTalkRadio, CallidusCloud, Engility, Fareportal, John Hancock, PetRays, and Softpro. Contact: Jill Rankin
303-405-2002
This e-mail address is being protected from spambots. You need JavaScript enabled to view it Logo - http://photos.prnewswire.com/prnh/20140318/DC85712LOGO To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/falcon-physician-honored-as-gold-stevie-award-winner-in-2015-american-business-awards-300105853.html SOURCE Falcon Physician Copyright (C) 2015 PR Newswire. All rights reserved

...

 
<< Start < Prev 131 132 133 134 135 136 137 138 139 140 Next > End >>

Page 132 of 4210
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.